CXCL1 and its receptor, CXCR2, mediate murine sickle cell vaso-occlusion during hemolytic transfusion reactions
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Hemolytic transfusion reactions (HTRs) can produce serious and potentially life-threatening complications in sickle cell disease (SCD) patients; however, the mechanisms underlying these complications remain undetermined. We established a model of alloimmune, IgG-mediated HTRs in a well-characterized humanized murine model of SCD. HTRs induced acute vaso-occlusive crisis (VOC), resulting in shortened survival of SCD mice. Acute VOC was associated with elevated circulating inflammatory chemokine levels, including striking elevation of the levels of the neutrophil chemoattractant CXCL1. Recombinant CXCL1 administration was sufficient to induce acute VOC in SCD mice, characterized by leukocyte recruitment in venules, capture of circulating red blood cells, reduction of venular flow, and shortened survival. In contrast, blockade of the CXCL1 receptor, CXCR2, prevented HTR-elicited acute VOC and prolonged survival in SCD mice. These results indicate that CXCL1 is a key inflammatory mediator of acute VOC in SCD mice. Targeted inhibition of CXCL1 and/or CXCR2 may therefore represent a new therapeutic approach for acute VOC in SCD patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Transgenic Knockout Mice with Exclusively Human Sickle Hemoglobin and Sickle Cell Disease
Pászty, C., Brion, C. M., Manci, E., Witkowska, H. E., Stevens, M. E., Mohandas, N., & Rubin, E. M. (1997) · Science · doi:10.1126/science.278.5339.876 · Cited by 467
Research works printed but not linked: 22
- 10.1056/NEJM199904013401307 · DOI · Paper page
- 10.1172/JCI30920 · DOI · Paper page
- Morris, Hematology Am Soc Hematol Educ Program., 2008, 177, 10.1182/asheducation-2008.1.177 · DOI · Paper page
- Wayne, 1993, Blood., 81, 1109, 10.1182/blood.V81.5.1109.bloodjournal8151109 · DOI
- 10.1001/archinte.148.11.2485 · doi:10.1001/archinte.148.11.2485
- Vichinsky, 2001, Semin Hematol., 38, 14, 10.1016/S0037-1963(01)90056-3 · DOI
- Diamond, 1980, Ann Intern Med., 93, 231, 10.7326/0003-4819-93-2-231 · doi:10.7326/0003-4819-93-2-231
- 10.1053/j.seminhematol.2005.04.006 · doi:10.1053/j.seminhematol.2005.04.006
- Schirmer, 2007, Blood., 109, 3099, 10.1182/blood-2006-08-040139 · DOI
- 10.1182/blood-2008-01-132092 · DOI
- Meyer, 1998, Blood., 92, 3997, 10.1182/blood.V92.11.3997 · DOI
- 10.1046/j.1537-2995.1993.33193142304.x · doi:10.1046/j.1537-2995.1993.33193142304.x
- Rakic, 1999, Med Pregl., 52, 19
- Goncalves, 2001, Braz J Med Biol Res., 34, 1309, 10.1590/S0100-879X2001001000011 · DOI
- 10.1073/pnas.052522799 · DOI · Paper page
- 10.1182/blood-2007-04-084061 · DOI · Paper page
- Kaul, 2000, J Clin Invest., 106, 411, 10.1172/JCI9225 · DOI · Paper page
- 10.1002/ajh.20143 · DOI
- 10.1152/ajpheart.00986.2004 · DOI · Paper page
- Hidalgo, 2009, Nat Med., 15, 384, 10.1038/nm.1939 · DOI · Paper page
- Belperio, 2002, J Clin Invest., 110, 1703, 10.1172/JCI0215849 · DOI · Paper page
- 10.1089/jir.2009.0006 · DOI
Cited by
Pathophysiology of Sickle Cell Disease
Sundd, P., Gladwin, M. T., & Novelli, E. M. (2019) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-012418-012838 · Cited by 813
Vaso-occlusion in sickle cell disease: pathophysiology and novel targeted therapies
Manwani, D., & Frenette, P. S. (2013) · Blood · doi:10.1182/blood-2013-05-498311 · Cited by 428
“Targeted inhibition of this pathway may represent a new therapeutic approach for VOC.(26) Murine models of SCD support an important role of hemolysis in VOC as well.”
BackgroundSelf-citationZhang, D., Xu, C., Manwani, D., & Frenette, P. S. (2016) · Blood · doi:10.1182/blood-2015-09-618538 · Cited by 413
“In addition, hemolytic transfusion reactions (HTRs) induce lethal acute vaso-occlusion in a model of alloimmune, immunoglobulin-mediated HTRs in SCD mice.(59) These studies suggest that VOCand acute lung injurymay be interconnected by neutrophils, NETs, and hemolysis.”
BackgroundInfluentialSelf-citationYazdanbakhsh, K., Ware, R. E., & Noizat-Pirenne, F. (2012) · Blood · doi:10.1182/blood-2011-11-327361 · Cited by 404
Potential roles and targeted therapy of the CXCLs/CXCR2 axis in cancer and inflammatory diseases
Cheng, Y., Ma, X.-L., Wei, Y.-Q., & Wei, X.-W. (2019) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2019.01.005 · Cited by 344
Metadata
- Authors
- Jang, J.-E., Hod, E. A., Spitalnik, S. L., & Frenette, P. S.
- Venue
- Journal of Clinical Investigation
- Published
- 2011-04-01
- Volume
- 121
- Issue
- 4
- Pages
- 1397-1401
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2086395548
- Cited by
- 41
- References
- 1
- FWCI
- 2.17
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.